ARS Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ARS Pharmaceuticals, Inc. (SPRY) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $8.20 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $8.41, a 4.34% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $8.06, a 84.86% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $4.36, a 32.92% decline year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $6.50, a 314.01% increase year-over-year.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $8.66, a 33.03% increase from fiscal 2024.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $6.51, a 3.17% increase from fiscal 2023.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $6.31, a 320.67% increase from fiscal 2022.
- ARS Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.50, a 54.64% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.20 10-Q · filed 2026-08-13 | |||||||
| 2026-03-31 | $8.41 10-Q · filed 2026-05-15 | |||||||
| 2025-12-31 | $8.66 10-K · filed 2026-03-09 | |||||||
| 2025-09-30 | $8.69 10-Q · filed 2025-11-10 | |||||||
| 2025-06-30 | $8.60 10-Q · filed 2026-08-13 | |||||||
| 2025-03-31 | $8.06 10-Q · filed 2026-05-15 | |||||||
| 2024-12-31 | $6.51 10-K · filed 2026-03-09 | |||||||
| 2024-09-30 | $5.57 10-Q · filed 2025-11-10 | |||||||
| 2024-06-30 | $4.52 10-Q · filed 2025-08-13 | |||||||
| 2024-03-31 | $4.36 10-Q · filed 2025-05-14 | |||||||
| 2023-12-31 | $6.31 10-K · filed 2025-03-20 | |||||||
| 2023-09-30 | $6.31 10-Q · filed 2024-11-13 | |||||||
| 2023-06-30 | $6.31 10-Q · filed 2024-08-06 | |||||||
| 2023-03-31 | $6.50 10-Q · filed 2024-05-09 | |||||||
| 2022-12-31 | $1.50 10-K · filed 2024-03-21 | |||||||
| 2022-09-30 | $2.31 10-Q · filed 2023-11-09 | $2.82 10-Q · filed 2022-11-02 | ||||||
| 2022-06-30 | $2.31 10-Q · filed 2023-08-10 | $2.82 10-Q · filed 2022-08-11 | ||||||
| 2022-03-31 | $1.57 10-Q · filed 2023-05-15 | $3.26 10-Q · filed 2022-05-12 | ||||||
| 2021-12-31 | $0.97 10-K · filed 2023-03-23 | $22.15 10-K · filed 2022-03-31 | ||||||
| 2021-09-30 | $24.92 10-Q · filed 2022-11-02 | |||||||
| 2021-06-30 | $26.69 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | $33.32 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | $10.50 10-K · filed 2022-03-31 | |||||||
| 2020-09-30 | $1.47 10-Q · filed 2021-11-10 | |||||||
| 2020-06-30 | $0.38 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |